Drug policy down under: Australia's pharmaceutical benefits scheme

Health Care Financing Review

Volumn 25, Issue 3, 2004, Pages 55-67

  Duckett, Stephen J ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG PROGRAM; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH INSURANCE; PRESCRIPTION; REVIEW;

AUSTRALIA; DEVELOPED COUNTRIES; DRUG COSTS; HEALTH EXPENDITURES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS;

EID: 2642582532     PISSN: 01958631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Aroni, R., de Boer, R., Harvey, K.: The Viagra Affair: Evidence as the Terrain for Competing Partners. In Lin, V., and Gibson, B. (eds.): Evidence-Based Health Policy. Oxford University Press. South Melbourne, Victoria, Australia. 2003.
2. Australian Bureau of Statistics: 1995 National Health Survey: Summary of Results, Australia. Australian Bureau of Statistics. Number 4364.0. Canberra, Australia. 1997.
3. Beilby, J. J., and Silagy, C.A.: Trials of Providing Costing Information to General Practitioners: A Systematic Review. Medical Journal of Australia. 167(2):89-92, July 21, 1997.
4. Bessell, T. L., Hiller, J.E., Sansom, L.N.: Pharmacist Only Medicines. Australian and New Zealand Journal of Public Health 23(6):661-662, 1999.
5. Blendon, R. J., Schoen, C., DesRoches, C.M., et al.: Inequities in Health Care: A Five-Country Survey. Health Affairs 21(3):182-191, May/June 2002.
6. Britt, H., Miller, G.C., Knox, S., et al.: General Practice Activity in Australia 2000-01. Internet address: http://www.aihw.gov.au/publications/index.cfm?type=detail&id=7280 (Accessed 2004.)
7. Commonwealth Department of Health and Aged Care: National Medicines Policy. Internet address: http://www.nmp.health.gov.au/pdf/nmp2000.pdf (Accessed 2004.)
8. Day, R.: Pharmaceutical Company Promotion: Striking a Balance. Australia New Zealand Journal of Medicine 28:291-93, 1998.
9. Friedberg, M., Saffran, B., Stinson, T.J., et al.: Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology. JAMA 282(15):1453-1457, 1999.
10. George, B., Harris, A. Mitchell, A.: Reimbursement Decisions and the Implied Value of life: Cost Effectiveness Analysis Decisions to Reimburse Pharmaceuticals in Australia 1993-96. In Harris, A. (ed.): Economics and Health: 1997 Proceedings of the Nineteenth Australian Conference of Health Economists. School of Health Services Management, University of New South Wales. Sydney, Australia. 1998.
11. Goddard, M., Henry, D., Birkett, D.J.: Securing the Future of the Pharmaceutical Benefits Scheme. Daring to Dream: The Future of Australian Health Care. In Mooney, G., and Plant, A. (eds.) Black Swan Press. Perth, Australia. 2001.
12. Hailey, D.: Australian Economic Evaluation and Government Decisions on Pharmaceuticals, Compared to Assessment of Other Health Technologies. Social Science & Medicine 45(4):563-581, 1997.
13. Harris, A. H.: Economic Appraisal in the Regulation of Pharmaceuticals in Australia: Its Rationale and Potential Impact. The Australian Economic Review(2nd Quarter): 98-105, 1994.
14. Harvey, K., and Murray, M.: Medicinal Drug Policy. In Gardner, H. (ed.): The Politics of Health: The Australian Experience. Churchill Livingstone. Maryborough, Australia. 1995.
15. Henry, D.: Economic Analysis As an Aid to Subsidisation Decisions: The Development of Australian Guidelines for Pharmaceuticals. PharmacoEconomics 1(1):54-67, 1992.
16. Herxheimer, A.: Relationships between the Pharmaceutical Industry and Patients' Organisations. BMJ 326: 1208-1210, May 31, 2003.
17. Hill, S., Henry, D., Pekarsky, B., and Mitchell, A.: Economic Evaluation of Pharmaceuticals: What Are Reasonable Standards for Clinical Evidence-The Australian Experience. British Journal of Clinical Pharmacology 44(5):421-425, November 1997a.
18. Hill, S. R., Henry, D.D., and Smith, A.J.: Rising Prescription Drug Costs: Whose Responsibility? Medical Journal of Australia 167(1):6-7, July 7, 1997b.
19. Hill, S. R., Mitchell, A.S., and Henry, D.A.: Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283(16):2116-2121, 2000.
20. Lexchin, J., Bero, L.A., Djulbegovic, B., and Clark, O.: Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review. BMJ 326:1167-1177 May 31, 2003.
21. Liaw, S.T., Pearce, C.M., Chondros, P., et al.: Doctors' Perceptions and Attitudes to Prescribing within the Authority Prescribing System. Medical Journal of Australia 178(5):203-206, 2003.
22. Löfgren, H.: The Pharmaceuticals Benefit Scheme and the Shifting Paradigm of Welfare Policy. Australian Health Review 21(2):111-123, 1998.
23. Löfgren, H.: Generic Drugs: International Trends and Policy Developments in Australia. Centre for Strategic Economic Studies Working Paper No. 10. Victoria University of Technology. Melbourne, Australia. 2002.
24. Loke, T. W., Koh, F.C., and Ward, J.E.: Pharmaceutical Advertisement Claims in Australian Medical Publications. Medical Journal of Australia 177(6): 291-293, 2002.
25. Lokuge, K. and Denniss, R.: Trading its Our Health System? The Impact of the Australia-US Free Trade Agreement on the Pharmaceutical Benefits Scheme. The Australian Institute, Australian National University Discussion Paper Number 55. Canberra, Australia. 2003.
26. Marino, M.: Diabetes Drug Pleas Sparks Row. The Age. 2003. Internet address: http://www.theage.com. au/articles/2003/12/06/1070625578319.html (Accessed 2004.)
27. Maynard, A., and Bloor, K.: Dilemmas in Regulation of the Market for Pharmaceuticals. Health Affairs 22(3):31-41, May/June, 2003.
28. Mitchell, A.: Update and Evaluation of Australian Guidelines: Government Perspective. Medical Care 34(12):DS216-DS25, 1996.
29. Moulds, R. F. W.: Promoting and Advertising Therapeutic Goods: Trade Practices Commission Report on Self-Regulation. Medical Journal of Australia 157(8):513-514, October 1992.
30. Moynihan, R.: Who pays for the Pizza? Redefining the Relationships Between Doctors and Drug Companies. 1: Entanglement. BMJ 326:1189-1192, May 31, 2003.
31. Moynihan, R., Heath, I., and Henry, D.: Selling Sickness: The Pharmaceutical Industry and Disease Mongering. BMJ 324:886-891, April 13, 2002.
32. National Health Strategy: Issues in Pharmaceutical Drug Use in Australia. National Health Strategy Issues Paper Number 4. Canberra, Australia. 1992.
33. Neumann, P. J., Sandberg, E.A., Bell, C.M., et al.: Are Pharmaceuticals Cost-Effective? A Review of the Evidence. Health Affairs 19(2):92-109, March/April 2000.
34. Organisation for Economic Co-operation and Development: OECD Health Data 2003(Computer Package), OECD. Paris, France. 2003.
35. Productivity Commission: International Pharmaceutical Price Differences. Research Report Ansinfo. Canberra, Australia. 2001.
36. Roughead, E. E., Gilbert, A.L., Primrose, J.G., et al.: Report of the National Indicators: Evaluating the Quality Use of Medicines Component of Australia's National Medicines. Publication Production Unit, Commonwealth Department of Aged Care. Canberra, Australia. 1999.
37. Roughead, E. E., Gilbert, A.L., Primrose, J.G., and Sanson, L.N.: Drug-Related Hospital Admissions: A Review of Australian Studies Published 1988-1996. Medical Journal of Australia 168(8):405-408, April 20, 1998.
38. Salkeld, G., Mitchell, A., Hill, S.: Pharmaceuticals. In Mooney, R., and Scotton, R. (eds.): Economics and Australian Health Policy. Allan and Unwin. St Leonards, Australia. 1999.
39. Saltman, R. B. and Figueras, J.: European Health Care Reform: Analysis of Current Strategies. WHO Regional Publications, European Series Number 72. Copenhagen, Denmark. 1997.
40. Schoen, C.: Ageing and Health Policy: The Value of International Comparisons and the Potential of Surveys to Add a Missing Perspective. A Disease-Based Comparison of Health Systems. What Is Best and at What Cost? Paris, France. OECD: 339-350. 2003. Internet address: http://www.oecdwash.org/PUBS/BOOKS/RP033/rp033hlth.htm (Accessed 2004.)
41. Schofield, D.: Re-Examining the Distribution of Health Benefits in Australia: Who Benefits from the Pharmaceutical Benefits Scheme. Discussion Paper Number 36. National Centre for Social and Economic Modelling, University of Canberra. Canberra, Australia. 1998.
42. Shenfield, G. M., and Tasker, J.L.: History in the Making: The Evolution of Consumer Product Information (CPI). Medical Journal of Australia 166(8):425-428, April 21, 1997.
43. Sloan, C.: A History of the Pharmaceutical Benefits Scheme 1947-1992. Commonweath Department of Human Services and Health. Canberra, Australia. 1995.
44. Sweeny, K.: Trends in the Use and Cost of Pharmaceuticals under the Pharmaceutical Benefits Scheme. Centre for Strategic Economic Studies Working Paper Number 5. Victoria University of Technology. Melbourne, Australia. 2002.
45. Walker, A., Percival, R., Harding, A.: The Impact of Demographic and Other Changes on Expenditure on Pharmaceutical Benefits in 2020 in Australia. Discussion Paper Number 31. National Centre for Social and Economic Modelling, Faculty of Management. University of Canberra. Canberra, Australia. 1998.
46. Wright, D. J.: Profitability and Leakage under the PBS. The Drawing Board Digest, December 2003. Internet address: http://www.econ.usyd.edu.au/drawingboard (Accessed 2004.)
47. Wright, D.J.: The Drug Bargaining Game: Pharmaceutical Regulation in Australia. Journal of Health Economics. (in press).